Mr. Blome is the President & CEO for Bayer CropScience, LP and the Head of Crop Protection for the North American region. Mr. Blome brings more than 30 years of leadership experience in agriculture and is located in the Crop Science division’s North American headquarters in Research Triangle Park, NC.

Outside of Bayer, Mr. Blome serves as Founding Chairman of the Board for US Farming and Ranching Foundation, the Chairman of Inocucor (USA and Canada) and the Vice-Chair of CropLife America.

Mr. Blome grew up on a family corn and soybean farm in Hubbard, Iowa and is a degreed agronomist from Iowa State University. He is the 2013 recipient of the Henry A. Wallace Award from Iowa State University for outstanding leadership and service to agriculture.




Mr. Marvin has been a biotechnology entrepreneur and leader in the commercialization of new life sciences diagnostic and research technologies and products for more than 30 years.

Prior to joining Inocucor®, he was the president and CEO of Cairn Associates Inc., a biotechnology, life science and consumer products strategy development and financial advisory firm.

Most recently, Mr. Marvin was the president and CEO of IdentiGEN, Inc., a leading provider of DNA-based solutions to the agriculture and food industries. He was a co-founder of Nasdaq-traded Orchid BioSciences, a pioneer in human DNA identity testing, where he served as its chief operating officer, chief financial officer and senior vice president of corporate development.

Previously, Mr. Marvin was president and CEO of Diatron Corporation, a biomedical company developing fluorescence-based instrument systems for the clinical diagnostics industry.

His expertise includes strategic planning, business development, technical administration and operations at PepsiCo, Abbott Laboratories and Bayer AG, as well as domestic and international marketing and sales for the clinical diagnostics subsidiary of Boehringer Ingelheim.

Mr. Marvin is a serial entrepreneur with a track record of building exceptional value for stakeholders at several life science and agri-food companies. Formerly New Jersey’s CFO of the year, he has raised over $350 million in both private and public financings and completed nearly a dozen M&A transactions for his former companies. Mr. Marvin has served on the boards of several public and privately held companies and currently serves on the board of MicroBiome Therapeutics, Inc.

He earned a B.S. in microbiology from Ohio State University and an M.B.A. in organizational behavior and finance from Iona College.




Mr. Vachet has 22 years of operational, venture capital, secondary transaction and fund management experience of venture capital portfolios investing in high tech companies.

Having managed numerous investments and exits during his career, Mr. Vachet has built a solid track record. He has, among others, been part of successful teams at both Kirchner and Multiple Capital.

He also worked at Innovatech Montreal as Vice-President Information Technology and Communication. In this capacity, he was responsible for 44 high-tech start-up companies and five venture capital funds. From April 2004 to March 2005, he participated in the sale of Innovatech Montreal’s portfolio, the second largest transaction in a venture capital portfolio in Canada with its 108 companies and 15 funds.

Mr. Vachet has broad corporate governance experience at board level as well as on audit, HR, strategic and M&A committees. He has occupied numerous board functions and duties as a director and chairperson on more than 30 company boards over the past 15 years.

Early in his career, Mr. Vachet acquired operational experience in the commercialization of cleantech technologies (water, energy, waste and other industrial applications) in a large multinational corporation across North America and China (Lyonnaise des eaux – Degrémont).

Mr. Vachet holds a Chemical Engineering degree from École Polytechnique (Montreal) and an M.B.A. in Finance from HEC-Montreal.




Dr. Duyk is founder and Managing Partner of Circularis LP, a group focused on supporting technology-enabled companies that advance the circular economy and promote sustainability as well as resource efficiency. Prior to Circularis, Dr. Duyk was the Managing Director and Partner of TPG Alternative & Renewable Technologies/TPG Biotechnology from 2004 to 2017.

Prior to TPG, Dr. Duyk served on the Board of Directors and was President of Research and Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals and served as Vice President of Genomics. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and an Assistant Investigator of the Howard Hughes Medical Institute. While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health-funded Cooperative Human Linkage Center.

Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was awarded a post-doctoral fellowship from HHMI.

In addition to Inocucor, Dr. Duyk currently serves on the Board of Directors of Amyris (Nasdaq: AMRS), Elevance Renewable Sciences and Regen Holdings.

He also is a member of the Board of Directors and the executive committee for the American Society of Human Genetics. He is a trustee of Case Western Reserve University, where he chairs the finance committee and sits on the Executive committee. He is a member of the Institute Board of Directors of the Moffitt Cancer Center, where he chairs the R&D committee. He has also served as a member of the Scientific Advisory Boards for Bayer Crop Sciences and Lawrence Berkeley National Laboratory, Department of Energy.


John B. Elstrott, Ph.D.


Dr. John B. Elstrott is a high-profile entrepreneur and professor in the natural foods and venture capital worlds.

Among his many business associations, Dr. Elstrott served as Chairman of Whole Foods Market, Inc. and was a Director of the company for 12 years. He also co-founded and is Chairman of MicroBiome Therapeutics, LLC, a developer of novel non-prescription therapies that target prediabetes and newly diagnosed type 2 diabetes by interacting with the human microbiome. In the academic world, he is a Clinical Professor of Entrepreneurship and the founding Director of the Levy-Rosenblum Institute for Entrepreneurship at Tulane University’s Freeman School of Business.

Dr. Elstrott was recently named the 2013 Tulane Distinguished Entrepreneur and Social Entrepreneur of the Year. He is also Co-Founder and Partner Emeritus of Elstrott, Maurer & Hunnewell (EMH Strategy), a boutique strategy-consulting firm based in New Orleans, and a Director of Source Capital Corporation, Traditional Medicinals, Chocolove and NextFoods, Inc.

He holds a Ph.D. from the University of Colorado Boulder, and M.S. and B.S. degrees from Louisiana State University.